10/17/2025
Clinical results published in 2022 in Dermatology Times and SAGE Journals continue to highlight the long-term value of Nexgel’s SilverSeal® hydrogel dressing. In a double-blind surgical study, SilverSeal led to better-looking scars, less pain, and faster recovery, with significant improvements at 6 and 12 weeks compared to standard dressings.
Building on this foundation of innovation, Nexgel’s branded consumer products—including SilverSeal—drove over 65% of company sales in Q2 2025 as revenue doubled year-over-year. As demand grows for science-backed wound care, Nexgel is positioned at the forefront of the advanced hydrogel market.
Read the full study, https://loom.ly/3tfgLIE
[Sources: Dermatology Times, SAGE Journals, Nexgel Q2 2025 Earnings]